CELU Financial Statements | Balance Sheet, Income & Cash Flow Analysis
The financial statements for CELU (CELU) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.
See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.
Financial Statements
Related peers
Compare More →| RVPH Reviva Pharmaceuticals Holdings, Inc. | $0.89 +3.35% |
| FGEN FibroGen, Inc. | $9.07 -1.63% |
| E Eni S.p.A. | $54.22 -2.11% |
| BTAI BioXcel Therapeutics, Inc. | $1.05 -0.94% |
| BCAB BioAtla, Inc. | $4.50 +5.50% |
| TPST Tempest Therapeutics, Inc. | $2.12 -5.57% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $0.89 | +3.35% | 3.02 M | -0.16 | -5.48 | 0.00% | Buy | 351 |
| FGEN FibroGen, Inc. | $9.07 | -1.63% | 36.69 M | -0.71 | -12.85 | 0.00% | Hold | 29 |
| E Eni S.p.A. | $54.22 | -2.11% | 79.95 B | 29.63 | 1.83 | 2.23% | Hold | 435 |
| BTAI BioXcel Therapeutics, Inc. | $1.05 | -0.94% | 28.43 M | -0.18 | -5.73 | 0.00% | Buy | 1.31 |
| BCAB BioAtla, Inc. | $4.50 | +5.50% | 5.30 M | -0.09 | -50.50 | 0.00% | Hold | 21 |
| TPST Tempest Therapeutics, Inc. | $2.12 | -5.57% | 9.41 M | -0.33 | -6.33 | 0.00% | Hold | 171 |
Frequently Asked Questions
What are CELU's latest financial results?
Review CELU's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.
How has CELU's revenue and net income changed over time?
Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.
What is CELU's cash flow situation and liquidity?
Cash flow statements reveal how CELU generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.
How does CELU's financial performance compare to industry peers?
Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether CELU is outperforming or lagging within its sector.
Are CELU's financial statements showing sustainable profitability?
By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether CELU's profits are repeatable and supported by strong fundamentals.